@article{
 title = {Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial},
 type = {article},
 year = {2017},
 identifiers = {[object Object]},
 pages = {appi.ajp.2017.1},
 websites = {http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2017.17060647},
 month = {12},
 publisher = {American Psychiatric AssociationArlington, VA},
 day = {5},
 id = {a0ac9c4b-d57c-3920-b2d5-ac8c7dc10496},
 created = {2017-12-09T19:16:29.194Z},
 accessed = {2017-12-09},
 file_attached = {false},
 profile_id = {078d13e5-632a-3ebf-9e0e-51a0b2c2c66e},
 group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},
 last_modified = {2017-12-27T00:58:48.464Z},
 tags = {CA},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {true},
 hidden = {false},
 citation_key = {Grunebaum2017b},
 notes = {L.B.},
 private_publication = {false},
 abstract = {Objective: Pharmacotherapy to rapidly relieve suicidal ide-ation in depression may reduce suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major depressive disorder. Method: In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score $4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion (at day 1).},
 bibtype = {article},
 author = {Grunebaum, Michael F and Galfalvy, Hanga C and Choo, Tse-Hwei and Keilp, John G and Moitra, Vivek K and Parris, Michelle S and Marver, Julia E and Burke, Ainsley K and Milak, Matthew S and Sublette, Elizabeth and Oquendo, Maria A and Mann, J John},
 journal = {American Journal of Psychiatry}
}

{"_id":"omGDp4DynktnbaNya","bibbaseid":"grunebaum-galfalvy-choo-keilp-moitra-parris-marver-burke-etal-ketamineforrapidreductionofsuicidalthoughtsinmajordepressionamidazolamcontrolledrandomizedclinicaltrial-2017","downloads":0,"creationDate":"2017-12-09T23:41:03.154Z","title":"Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial","author_short":["Grunebaum, M., F.","Galfalvy, H., C.","Choo, T.","Keilp, J., G.","Moitra, V., K.","Parris, M., S.","Marver, J., E.","Burke, A., K.","Milak, M., S.","Sublette, E.","Oquendo, M., A.","Mann, J., J."],"year":2017,"bibtype":"article","biburl":null,"bibdata":{"title":"Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial","type":"article","year":"2017","identifiers":"[object Object]","pages":"appi.ajp.2017.1","websites":"http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2017.17060647","month":"12","publisher":"American Psychiatric AssociationArlington, VA","day":"5","id":"a0ac9c4b-d57c-3920-b2d5-ac8c7dc10496","created":"2017-12-09T19:16:29.194Z","accessed":"2017-12-09","file_attached":false,"profile_id":"078d13e5-632a-3ebf-9e0e-51a0b2c2c66e","group_id":"d9389c6c-8ab5-3b8b-86ed-33db09ca0198","last_modified":"2017-12-27T00:58:48.464Z","tags":"CA","read":false,"starred":false,"authored":false,"confirmed":"true","hidden":false,"citation_key":"Grunebaum2017b","notes":"L.B.","private_publication":false,"abstract":"Objective: Pharmacotherapy to rapidly relieve suicidal ide-ation in depression may reduce suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major depressive disorder. Method: In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score $4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion (at day 1).","bibtype":"article","author":"Grunebaum, Michael F and Galfalvy, Hanga C and Choo, Tse-Hwei and Keilp, John G and Moitra, Vivek K and Parris, Michelle S and Marver, Julia E and Burke, Ainsley K and Milak, Matthew S and Sublette, Elizabeth and Oquendo, Maria A and Mann, J John","journal":"American Journal of Psychiatry","bibtex":"@article{\n title = {Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial},\n type = {article},\n year = {2017},\n identifiers = {[object Object]},\n pages = {appi.ajp.2017.1},\n websites = {http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2017.17060647},\n month = {12},\n publisher = {American Psychiatric AssociationArlington, VA},\n day = {5},\n id = {a0ac9c4b-d57c-3920-b2d5-ac8c7dc10496},\n created = {2017-12-09T19:16:29.194Z},\n accessed = {2017-12-09},\n file_attached = {false},\n profile_id = {078d13e5-632a-3ebf-9e0e-51a0b2c2c66e},\n group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},\n last_modified = {2017-12-27T00:58:48.464Z},\n tags = {CA},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n citation_key = {Grunebaum2017b},\n notes = {L.B.},\n private_publication = {false},\n abstract = {Objective: Pharmacotherapy to rapidly relieve suicidal ide-ation in depression may reduce suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major depressive disorder. Method: In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score $4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion (at day 1).},\n bibtype = {article},\n author = {Grunebaum, Michael F and Galfalvy, Hanga C and Choo, Tse-Hwei and Keilp, John G and Moitra, Vivek K and Parris, Michelle S and Marver, Julia E and Burke, Ainsley K and Milak, Matthew S and Sublette, Elizabeth and Oquendo, Maria A and Mann, J John},\n journal = {American Journal of Psychiatry}\n}","author_short":["Grunebaum, M., F.","Galfalvy, H., C.","Choo, T.","Keilp, J., G.","Moitra, V., K.","Parris, M., S.","Marver, J., E.","Burke, A., K.","Milak, M., S.","Sublette, E.","Oquendo, M., A.","Mann, J., J."],"urls":{"Website":"http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2017.17060647"},"bibbaseid":"grunebaum-galfalvy-choo-keilp-moitra-parris-marver-burke-etal-ketamineforrapidreductionofsuicidalthoughtsinmajordepressionamidazolamcontrolledrandomizedclinicaltrial-2017","role":"author","downloads":0},"search_terms":["ketamine","rapid","reduction","suicidal","thoughts","major","depression","midazolam","controlled","randomized","clinical","trial","grunebaum","galfalvy","choo","keilp","moitra","parris","marver","burke","milak","sublette","oquendo","mann"],"keywords":[],"authorIDs":[]}